# Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Source: https://onco.cc/trials/nct06449209/  
OnCo record `nct06449209` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Etoposide, Carboplatin, Paclitaxel / nab-paclitaxel in small-cell lung cancer, run by BioNTech SE, active and no longer recruiting.

## Summary

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy is a phase 2 interventional study registered as NCT06449209 by BioNTech SE, with 110 participants planned, started 2024-08-05 and due to reach its primary completion in 2027-06. Interventions recorded: BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel. Conditions listed: Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06449209
- Phase: 2
- Setting: A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer
- Sponsor: BioNTech SE
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT06449209: https://clinicaltrials.gov/study/NCT06449209

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Topotecan](https://onco.cc/drugs/topotecan/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct06449209.json